Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
© 2023. The Author(s)..
INTRODUCTION: Teclistamab is the first approved B cell maturation antigen × CD3 bispecific antibody with precision dosing for the treatment of triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). We compared the effectiveness of teclistamab in MajesTEC-1 versus real-world physician's choice of therapy (RWPC) in patients from the prospective, non-interventional LocoMMotion and MoMMent studies.
METHODS: Patients treated with teclistamab from MajesTEC-1 (N = 165) were compared with an external control arm from LocoMMotion (N = 248) or LocoMMotion + MoMMent pooled (N = 302). Inverse probability of treatment weighting adjusted for imbalances in prognostic baseline characteristics. The relative effect of teclistamab versus RWPC for overall response rate (ORR), very good partial response or better (≥ VGPR) rate, and complete response or better (≥ CR) rate was estimated with an odds ratio using weighted logistic regression transformed into a response-rate ratio (RR) and 95% confidence interval (CI). Weighted proportional hazards regression was used to estimate hazard ratios (HRs) and 95% CIs for duration of response (DOR), progression-free survival (PFS), and overall survival (OS).
RESULTS: Baseline characteristics were well balanced between treatment cohorts after reweighting. Patients treated with teclistamab had significantly improved outcomes versus RWPC in LocoMMotion: ORR (RR [95% CI], 2.44 [1.79-3.33]; p < 0.0001), ≥ VGPR (RR 5.78 [3.74-8.93]; p < 0.0001), ≥ CR (RR 113.73 [15.68-825.13]; p < 0.0001), DOR (HR 0.39 [0.24-0.64]; p = 0.0002), PFS (HR 0.48 [0.35-0.64]; p < 0.0001), and OS (HR 0.64 [0.46-0.88]; p = 0.0055). Teclistamab versus RWPC in LocoMMotion + MoMMent also had significantly improved outcomes: ORR (RR 2.41 [1.80-3.23]; p < 0.0001), ≥ VGPR (RR 5.91 [3.93-8.88]; p < 0.0001), ≥ CR (RR 132.32 [19.06-918.47]; p < 0.0001), DOR (HR 0.43 [0.26-0.71]; p = 0.0011), PFS (HR 0.49 [0.37-0.66]; p < 0.0001), and OS (HR 0.69 [0.50-0.95]; p = 0.0247).
CONCLUSION: Teclistamab demonstrated significantly improved effectiveness over RWPC in LocoMMotion ± MoMMent, emphasizing its clinical benefit as a highly effective treatment for patients with TCE RRMM.
TRIAL REGISTRATION: MajesTEC-1, ClinicalTrials.gov NCT03145181 (phase 1) and NCT04557098 (phase 2); LocoMMotion, ClinicalTrials.gov NCT04035226; MoMMent, ClinicalTrials.gov NCT05160584.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Advances in therapy - 41(2024), 2 vom: 07. Feb., Seite 696-715 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Moreau, Philippe [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 08.02.2024 Date Revised 14.03.2024 published: Print-Electronic ClinicalTrials.gov: NCT05160584, NCT04557098, NCT04035226, NCT03145181 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12325-023-02738-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366013505 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366013505 | ||
| 003 | DE-627 | ||
| 005 | 20240314234746.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12325-023-02738-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1328.xml |
| 035 | |a (DE-627)NLM366013505 | ||
| 035 | |a (NLM)38110653 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Moreau, Philippe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.02.2024 | ||
| 500 | |a Date Revised 14.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT05160584, NCT04557098, NCT04035226, NCT03145181 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a INTRODUCTION: Teclistamab is the first approved B cell maturation antigen × CD3 bispecific antibody with precision dosing for the treatment of triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). We compared the effectiveness of teclistamab in MajesTEC-1 versus real-world physician's choice of therapy (RWPC) in patients from the prospective, non-interventional LocoMMotion and MoMMent studies | ||
| 520 | |a METHODS: Patients treated with teclistamab from MajesTEC-1 (N = 165) were compared with an external control arm from LocoMMotion (N = 248) or LocoMMotion + MoMMent pooled (N = 302). Inverse probability of treatment weighting adjusted for imbalances in prognostic baseline characteristics. The relative effect of teclistamab versus RWPC for overall response rate (ORR), very good partial response or better (≥ VGPR) rate, and complete response or better (≥ CR) rate was estimated with an odds ratio using weighted logistic regression transformed into a response-rate ratio (RR) and 95% confidence interval (CI). Weighted proportional hazards regression was used to estimate hazard ratios (HRs) and 95% CIs for duration of response (DOR), progression-free survival (PFS), and overall survival (OS) | ||
| 520 | |a RESULTS: Baseline characteristics were well balanced between treatment cohorts after reweighting. Patients treated with teclistamab had significantly improved outcomes versus RWPC in LocoMMotion: ORR (RR [95% CI], 2.44 [1.79-3.33]; p < 0.0001), ≥ VGPR (RR 5.78 [3.74-8.93]; p < 0.0001), ≥ CR (RR 113.73 [15.68-825.13]; p < 0.0001), DOR (HR 0.39 [0.24-0.64]; p = 0.0002), PFS (HR 0.48 [0.35-0.64]; p < 0.0001), and OS (HR 0.64 [0.46-0.88]; p = 0.0055). Teclistamab versus RWPC in LocoMMotion + MoMMent also had significantly improved outcomes: ORR (RR 2.41 [1.80-3.23]; p < 0.0001), ≥ VGPR (RR 5.91 [3.93-8.88]; p < 0.0001), ≥ CR (RR 132.32 [19.06-918.47]; p < 0.0001), DOR (HR 0.43 [0.26-0.71]; p = 0.0011), PFS (HR 0.49 [0.37-0.66]; p < 0.0001), and OS (HR 0.69 [0.50-0.95]; p = 0.0247) | ||
| 520 | |a CONCLUSION: Teclistamab demonstrated significantly improved effectiveness over RWPC in LocoMMotion ± MoMMent, emphasizing its clinical benefit as a highly effective treatment for patients with TCE RRMM | ||
| 520 | |a TRIAL REGISTRATION: MajesTEC-1, ClinicalTrials.gov NCT03145181 (phase 1) and NCT04557098 (phase 2); LocoMMotion, ClinicalTrials.gov NCT04035226; MoMMent, ClinicalTrials.gov NCT05160584 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a LocoMMotion | |
| 650 | 4 | |a MajesTEC-1 | |
| 650 | 4 | |a MoMMent | |
| 650 | 4 | |a Relapsed or refractory multiple myeloma | |
| 650 | 4 | |a Teclistamab | |
| 650 | 4 | |a Triple-class exposed | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Mateos, María-Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez Garcia, Maria Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Einsele, Hermann |e verfasserin |4 aut | |
| 700 | 1 | |a De Stefano, Valerio |e verfasserin |4 aut | |
| 700 | 1 | |a Karlin, Lionel |e verfasserin |4 aut | |
| 700 | 1 | |a Lindsey-Hill, Joanne |e verfasserin |4 aut | |
| 700 | 1 | |a Besemer, Britta |e verfasserin |4 aut | |
| 700 | 1 | |a Vincent, Laure |e verfasserin |4 aut | |
| 700 | 1 | |a Kirkpatrick, Suriya |e verfasserin |4 aut | |
| 700 | 1 | |a Delforge, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Perrot, Aurore |e verfasserin |4 aut | |
| 700 | 1 | |a van de Donk, Niels W C J |e verfasserin |4 aut | |
| 700 | 1 | |a Pawlyn, Charlotte |e verfasserin |4 aut | |
| 700 | 1 | |a Manier, Salomon |e verfasserin |4 aut | |
| 700 | 1 | |a Leleu, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez-Lopez, Joaquin |e verfasserin |4 aut | |
| 700 | 1 | |a Ghilotti, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Diels, Joris |e verfasserin |4 aut | |
| 700 | 1 | |a Morano, Raúl |e verfasserin |4 aut | |
| 700 | 1 | |a Albrecht, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Strulev, Vadim |e verfasserin |4 aut | |
| 700 | 1 | |a Haddad, Imène |e verfasserin |4 aut | |
| 700 | 1 | |a Pei, Lixia |e verfasserin |4 aut | |
| 700 | 1 | |a Kobos, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Smit, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Slavcev, Mary |e verfasserin |4 aut | |
| 700 | 1 | |a Marshall, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Weisel, Katja |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d 1990 |g 41(2024), 2 vom: 07. Feb., Seite 696-715 |w (DE-627)NLM085859427 |x 1865-8652 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2024 |g number:2 |g day:07 |g month:02 |g pages:696-715 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12325-023-02738-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2024 |e 2 |b 07 |c 02 |h 696-715 | ||